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Background: Subanesthetic doses of ketamine, an N-methyl-d-aspartate receptor antagonist 
used as an adjuvant to opioid for the treatment of pain in adults with acute and chronic pain, 
have been shown, in some instances, to improve pain intensity and to decrease opioid intake. 
However, less is known about the role of ketamine in pain management in children, adolescents, 
and young adults.
Purpose: We examined the effects of subanesthetic ketamine on pain intensity and opioid 
intake in children, adolescents, and young adults with acute and chronic pain syndromes treated 
in an inpatient setting.
Methods: This is a longitudinal cohort study of patients treated with subanesthetic ketamine 
infusions in regular patient care units in a tertiary pediatric hospital. Primary outcomes included 
changes in pain scores and morphine-equivalent intake.
Results: The study cohort included 230 different patients who during 360 separate hospital 
admissions received subanesthetic ketamine infusions for pain management. Overall, ketamine 
infusions were associated with significant reductions in mean pain scores from baseline (mean 
pain scores 6.64 [95% CI: 6.38–6.90]) to those recorded on the day after discontinuation of 
ketamine (mean pain scores 4.38 [95% CI: 4.06–4.69]), p<0.001. Importantly, the effect of 
ketamine on pain scores varied according to clinical diagnosis (p=0.011), infusion duration 
(p=0.004), and pain location (p=0.004). Interestingly, greater reductions in pain scores were 
observed in patients with cancer pain and patients with pain associated with pancreatitis and 
Crohn’s disease. There were no records of psychotomimetic side effects requiring therapy.
Conclusion: These data suggest that administration of subanesthetic ketamine for pain manage-
ment is feasible and safe in regular inpatient care units and may benefit children, adolescents, 
and young adults with acute and chronic pain. This study is informative and can be helpful 
in determining sample and effect sizes when planning clinical trials to determine the role of 
subanesthetic ketamine infusions for pain management in pediatric patients.
Keywords: cancer pain, sickle cell disease, CRPS, postoperative pain, chronic pain, acute pain
Introduction
Ketamine has been used clinically since the 1960s as a general anesthetic.1 A decade 
after its approval by the US Food and Drug Administration, researchers showed that ket-
amine reduces the excitatory response to N-methyl-d-aspartic acid (NMDA) in central 
neurons, thus revealing its NMDA receptor antagonism properties2 and advancing our 
understanding of the pharmacology of ketamine. Currently, clinicians use ketamine as 
a general anesthetic less frequently, given its emergence psychotomimetic effects and 
findings of neurotoxic effects shown in the developing brain of animals.3 Conversely, 
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over the past decade, researchers have explored the effect of 
subanesthetic doses of ketamine as an antidepressant4 and 
as an analgesic.5,6
The use of subanesthetic ketamine as an analgesic is sup-
ported by evidence, from both animal and human studies, 
implicating activation of NMDA receptors in the pathobiol-
ogy of nociceptive, inflammatory, and neuropathic pain and 
in central sensitization.7 In addition, activation of NMDA 
receptors has also been shown in animals8 and in human 
experimental studies9 to play a role in settings where acute or 
chronic use of opioids is associated with tolerance or opioid-
induced hyperalgesia. Therefore, based on these preclinical 
findings, ketamine has been examined clinically as an adju-
vant to opioids for the treatment of acute and chronic pain 
and in settings of opioid-induced hyperalgesia.6,10 However, 
among clinical studies, there has been a great variability in 
ketamine doses and duration of administration. Additionally, 
the beneficial effects of ketamine have not been consistently 
reported, and some groups have been unable to show opioid-
sparing effects of ketamine in clinical settings associated with 
opioid-induced hyperalgesia.11,12 Similarly, in chronic pain, 
there are no definitive data supporting the use of ketamine 
for the treatment of chronic regional pain syndrome (CRPS) 
or other types of chronic pain.13 Further, in critical reviews of 
available trials, researchers can only conclude that there might 
be a beneficial role for ketamine as an adjuvant to opioids to 
treat pain in the postoperative period, cancer pain, and chronic 
pain.9,12,14,15 Consequently, as outlined in clinical guidelines, 
the evidence to support the use of ketamine for the treatment 
of acute and chronic pain is at best moderate.16,17
However, despite lack of conclusive clinical evidence to 
support its use, clinicians from various disciplines in many 
countries continue to use ketamine as an adjuvant to opioids 
for acute and chronic pain management.18–21 Some argue that 
in the setting of limited effective pharmacologic options, 
one might be left with no alternative other than less studied 
strategies such as ketamine infusions. Our institution has 
used subanesthetic ketamine (defined as not >1 mg/kg/h) 
to treat acute and chronic pain in children, adolescents, and 
young adults since 2006. We have previously reported our 
experience using ketamine for the treatment of cancer pain, 
postoperative, and chronic pain.5,11 In this study, we sought to 
examine the use of subanesthetic ketamine in a large number 
of patients admitted to a tertiary pediatric hospital whose pain 
proved unresponsive to routine pharmacologic interventions. 
Specifically, we sought to determine the overall effect of 
ketamine on pain scores and opioid intake, to identify factors 
associated with larger or smaller effects and to examine the 
frequency with which ketamine was associated with clini-
cally meaningful reductions in pain scores and opioid intake.
Methods
Data collection
The Children’s National Health System Institutional 
Review Board approved this longitudinal cohort study 
and a waiver for written informed consent in 2014 
(Pro00004569). Requirement for patient written consent to 
review their records was waived as this was a minimal risk 
study and the data collected were devoid of patient identi-
fiers. Patients who had received subanesthetic doses of 
ketamine for pain management were eligible for inclusion 
in this study. We reviewed a list of all patients (obtained 
from the hospital pharmacy records) who were admitted 
between January 2006 and April 2014 and had received 
an order for continuous infusion of intravenous ketamine. 
Patients who lacked a pain medicine consult, underwent a 
spinal fusion procedure (those patients were part of a pre-
viously reported investigational study11), had incomplete 
record of pain scores and/or opioid intake, or received 
ketamine only for the purpose of sedation were excluded. 
Data collected included sex, age, race, ketamine infusion 
duration, pain duration (acute vs chronic), pain diagnoses 
(vaso-occlusive episodes [VOE], visceral, CRPS, headache, 
or other [mucositis, diabetic neuropathy, neurofibromatosis, 
and postural orthostatic tachycardia syndrome]), primary 
clinical diagnosis (accidental trauma, surgical trauma, and 
postoperative pain [patients who had a planned surgical 
procedure during hospitalization], functional gastrointes-
tinal disorder [chronic and/or recurrent gastrointestinal 
symptoms with no identified etiology], inflammatory dis-
ease [pancreatitis or Crohn’s disease], sickle cell disease, 
malignancy, or other), and primary pain location. Patients 
with pain in more than two locations were classified as hav-
ing generalized pain. From the medical charts, we retrieved 
documentation of hemodynamic changes that warranted 
treatment with vasoactive agents, as well as reports of 
psychotropic effects, nausea, vomiting, and changes in 
sleep pattern. All pain scores recorded throughout admis-
sion days were collected. We then calculated average daily 
pain scores before (day prior to ketamine administration) 
and after (24 h, 48 h, and on the day after discontinuation) 
ketamine infusion. Pain scores were measured using the 
Numeric Rating Scale (NRS), the Wong-Baker FACES®, or 
the Face, Legs, Activity, Cry, and Consolability (FLACC), 
as appropriate. At the times indicated earlier, we also col-
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Ketamine for pain management
oral  morphine-equivalent (per body weight in kilograms) 
intake using the opioid conversion tool available at www.
globalrph.com/narcoticonv.htm.22
Outcomes
The primary outcome was change in average pain scores 
from baseline to postketamine infusion. Secondary out-
comes included changes in oral morphine-equivalent intake 
from baseline measurements to postketamine infusion and 
proportion of ketamine infusions that resulted in clinically 
meaningful reductions in pain scores and opioid intake. 
We defined clinically meaningful change in pain scores or 
opioid intake as a ≥20% reduction in pain scores and in 
morphine-equivalent intake from baseline to the day after 
ketamine discontinuation (day after ketamine - baseline/
baseline ¥100). Such a decline in pain score (20%) is larger 
than the 12.5% decrease in pain score suggested by others 
as being minimally clinically significant for adolescents with 
chronic pain.23
Ketamine administration
At our institution, ketamine prescribed by the Pain Medicine 
Division can be administered on regular inpatient care units 
where oxygen delivery set-up, suction, and resuscitation 
equipment are available. Trained nurses administer ketamine 
infusions using a locked infusion pump and patients are 
maintained on a cardiorespiratory monitor (heart and respi-
ratory rate, blood pressure, and pulse oximeter). Criteria to 
receive subanesthetic doses of ketamine infusions include 
inadequate analgesia with standard pain therapy, opioid toler-
ance associated with undesirable side effects, opioid-induced 
hyperalgesia, neuropathic pain, postoperative pain in patients 
in whom opioid use was undesirable, or an opioid-sparing 
effect was needed for clinical reasons. Ketamine infusions 
used for end-of-life care were excluded. Exclusion criteria 
for ketamine administration include history of psychosis, 
intracranial hypertension, severe labile hypertension, or 
poorly controlled cardiac arrhythmia, hypersensitivity to 
ketamine, and age <3 months.
In our institution, ketamine infusions order sets are avail-
able, and the suggested starting doses are as follows: 1) for 
opioid naive patients, ketamine is started at 0.05–0.4 mg/
kg/h; 2) for opioid tolerant patients (as documented by 
the pain service), 0.05–1 mg/kg/h; and 3) for patients with 
documented opioid-induced hyperalgesia, 1 mg/kg/h. Dur-
ing infusions, ketamine doses could be titrated according to 
its indication and pain scores up to 1 mg/kg/h as allowed by 
the Board of Nursing.
Statistical analysis
The distributions of raw pain scores, daily opioid intake, and 
changes over time were tested for normality. Because the 
data were skewed, the Wilcoxon signed-rank test was used to 
test for statistical significance of within-individuals changes 
between baseline and posttreatment outcome measurements.
Box plots were used to examine how the individual-
level changes (between baseline and the day after ketamine 
discontinuation) in raw pain scores and daily opioid intake 
were distributed across the subgroups of the eight patient 
characteristics (age, sex, race, duration of pain, clinical diag-
nosis, type of pain, location of pain, and duration of ketamine 
infusion), and the distributions were tested for normality. 
Because the data were skewed for certain characteristics, 
nonparametric tests were used for all statistical analyses.
The Kruskal–Wallis test was used to compare the dis-
tribution of values across the subgroups of each patient 
characteristic separately. When an overall difference was 
detected, Dunn’s test (with a Bonferroni adjustment for 
multiple comparisons) was then used to compare all possible 
pairs of subgroups and identify any statistically significant 
detectable differences.
The proportion of patients (95% confidence interval [CI]) 
who achieved clinically meaningful reductions in pain and 
daily opioid intake were graphed in order to visually compare 
how the proportions varied across the subgroups of all eight 
patient characteristics.
Fisher’s exact test was used to examine whether the pro-
portions varied across the subgroups of sex, race, duration 
of pain, clinical diagnosis, type of pain, or location of pain. 
A nonparametric test for trend was used to examine whether 
the proportion of patients with a clinically meaningful reduc-
tion in pain scores and opioid intake systematically declined 
across ordered age groups or by the duration of ketamine 
infusion.
Stata 14.1/IC (StataCorp LLC, College Station, TX, 
USA) was used to conduct all analyses. p-values <0.05 were 
considered statistically significant except when Bonferroni’s 
correction for multiple comparisons was applied. In those 
instances, the statistically significant p-value was calculated 
as 0.05/the total number of comparisons.
Results
Study cohort
We reviewed 1542 records, containing orders for subanes-
thetic ketamine administration (Figure 1). Records containing 
ketamine orders not written by the Pain Medicine Division 
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spinal fusion (ketamine was administered as part of a 
postoperative pain management and previously reported11) 
were excluded. Two hundred and fifty-one patients and 441 
infusions, which occurred between January 2006 and April 
2014, met the study eligibility criteria. Of the 441 remaining 
records, 57 were excluded as pain scores, and/or opioid intake 
data were missing during the first or second day of ketamine 
administration or for the 24 h after discontinuation of ket-
amine. Records from 24 ketamine infusions were eliminated 
because they consisted of a second ketamine infusion during 
a single hospital admission. The final study cohort included 
data from 230 different patients who, during 360 separate 
hospital admissions, received subanesthetic ketamine infu-
sions for pain therapy. Of those, 180 patients were admitted 
once, while the other 50 were each admitted between two 
and ten times. For the purpose of this study, each admission 
was considered an independent event.
Patients
Patient characteristics at the time of first ketamine infusion 
are listed in Table 1. The median age was 14 years (interquar-
tile range: 10–17 years). Over the 360 ketamine infusions, 
most patients were from 12 to 18 years of age (58%), 6 to 
11 years (17%), 19 to 21 years (14%), 3 to 5 years (5%), 
>22 years (4%), and 1.1 to 2.9 years (3%). Most ketamine 
infusions lasted 3 days (26%).
Seventy-eight percent of infusions (280) were adminis-
tered to patients with acute pain and 22% to patients with 
chronic pain. Additionally, most ketamine infusions (50%) 
were administered to patients with sickle cell disease who had 
been admitted for VOE, whereas 17% who had postoperative 
pain after surgical trauma and 13% had malignancy-associ-
ated pain (Table 2). Pain locations are listed in Table 3. Most 
patients had generalized pain (25%), followed by abdominal 
(22%), lower extremity (21%), and chest (15%) pain.
Primary outcome
We collected average pain scores on the day prior to initia-
tion of ketamine and on the first day of ketamine infusion. 
In the hospital admissions (n=331 of 441) where both values 
were originally available in the electronic medical record, 
the average pain score on the day prior to ketamine initiation 
(6.85 [95% CI: 6.58–7.11]) and on the first day of ketamine 
infusion were similar (6.84 [95% CI: 6.59–7.08]), p=0.499. 
Given that in all infusions, the average pain score values 
were available on the first day of infusion, we considered 
that as the baseline pain score for the final study cohort of 
360 hospital admissions.
Overall, ketamine infusions were associated with signifi-
cant reductions in average pain scores from the first day of 
Figure 1 Flowchart indicating patient selection and exclusion criteria.
1542 medical records contained
orders for ketamine administration
57 infusions excluded:
24 infusions excluded:
• Missing pain scores or
   morphine intake
• Repeated ketamine
  infusions during one
  admission
1101 records excluded
• Ketamine not ordered by
  pain medicine
• Incomplete records
• Spinal fusion patients
251 patients received 441
infusions ordered by pain
medicine
230 patients, 360 ketamine
infusions ordered by pain
medicine included in the analysis
Table 1 Characteristics of 230 patients who received 360 


























Six or more 90 (25)
Notes: aPatient’s characteristics are those at the time of first ketamine infusion. 
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Ketamine for pain management
infusion (6.65 [95% CI: 6.39–6.91]) to the day after discon-
tinuation of ketamine (4.38 [95% CI: 4.06–4.69]), p<0.001.
The effect of ketamine infusions on raw pain scores 
(within-individual change) was similar comparing all age 
groups (p=0.842), males and females (p=0.065), all races 
(p=0.721), acute and chronic pain (p=0.460), and pain 
types (p=0.894), data not shown. In contrast, the effect of 
ketamine infusions on pain scores varied according to clini-
cal diagnosis (p=0.01), infusion duration (p=0.004), and pain 
location (p=0.004, Figure 2). Specifically, greater median 
reductions in pain scores were observed in patients with 
malignancy-associated pain and patients with inflammatory 
disease (pancreatitis and Crohn’s disease), whereas the low-
est were in patients with functional gastrointestinal disorder 
and other (cystic fibrosis, diabetes mellitus, neurofribroma-
tosis 1, postural orthostatic tachycardia syndrome, and two 
cases simply coded as other, p=0.011 for overall difference, 
Figure 2A). Regarding infusion durations, longer ketamine 
infusions yielded greater median reductions in pain scores 
(p=0.004, Figure 2B). Further, patients with back (-2.57 
[-4.75, -1.56], median [25th, 75th percentiles respectively]), 
abdominal (-1.91 [-3.88, -0.6]), and generalized (-1.87 
[-3.43, -0.75]) pain had the greatest reductions, whereas 
patients with chest pain (-0.5 [-2.37, -0.33]) had the lowest 
reductions in pain scores (p=0.004 for overall difference).
Secondary outcomes
Regarding opioid intake, ketamine infusions were associated 
with significant decreases in overall average oral morphine-
equivalent intake from the first day of infusion (2.74 mg/kg/d 
[2.47–3.00], mean [95% CI]) to the day after discontinuation 
of ketamine (2.06 mg/kg/d [1.81–2.31]), p<0.001. There 
was no impact of age, sex, race, pain duration (acute vs 
chronic), or pain location or type on the effect of ketamine 
on oral morphine-equivalent intake (all p≥0.322). However, 
the ketamine effect on opioid intake varied according to 
clinical diagnosis (p=0.030, Figure 2C) and duration of 
infusion (p=0.022, Figure 2D). Specifically, greater median 
reductions in opioid intake were observed in patients with 
malignancy-associated pain and patients with sickle cell 
disease, whereas lesser reductions were observed in patients 
with accidental trauma and postoperative pain after surgical 
trauma (p=0.030 for overall difference, Figure 2C). Regard-
ing ketamine infusion duration, similar to the observation of 
reduction in pain scores, longer ketamine infusions yielded 
greater reductions in oral morphine-equivalent intake 
(p=0.022, Figure 2D).
During ketamine administration, there were no records 
of hallucinations, changes in sleep pattern, or hemodynamic 
changes or arrhythmias requiring therapy in any patient.
Clinically meaningful reduction in pain 
score and morphine-equivalent intake
We then examined the proportion of ketamine infusions 
that yielded clinically meaningful changes in pain scores 
and opioid intake, here defined as a ≥20% reduction in pain 
scores and a ≥20% reduction in morphine-equivalent intake 
after discontinuation of the infusion compared to baseline 
levels, respectively. Overall, there was a ≥20% reduction in 
pain scores in 58% of all ketamine infusions. The proportion 
of infusions that yielded a 20% or greater reduction in pain 
scores varied according to clinical diagnosis (p=0.003), pain 
location (p=0.012), age (p=0.039), and duration of infusion 
(p=0.017, Figure 3). For example, the highest proportion of 
infusions associated with clinically meaningful reduction in 
pain scores were observed among infusions administered to 
cancer patients and patients with inflammatory diseases and 
the lowest among patients with functional gastrointestinal 
disorders (Figure 3A). There was a trend for higher frequency 
of meaningful reduction in pains scores in males (63%) than 
in females (54%), p=0.056. Conversely, the frequency of 
Table 2 Clinical diagnosis for patients who received 360 infusions 
of ketamine in an inpatient settinga
Associated diagnoses n (%)
Sickle cell disease 181 (50)
Surgical trauma (postoperative pain) 61 (17)
Malignancy 46 (13)
Inflammatory diseases 18 (5)
Accidental trauma 16 (4)
Functional gastrointestinal disorder 14 (4)
Other 24 (7)
Notes: aClinical diagnoses were those recorded in the pain medicine consultation. 
Inflammatory diseases included pancreatitis and Crohn’s disease. Other included 
cystic fibrosis, diabetes mellitus, neurofibromatosis 1, postural orthostatic 
tachycardia syndrome, and two cases simply coded as “other”.
Table 3 Pain location in 360 admissions where ketamine was 
administered to treat pain in a tertiary care pediatric centera
Pain location n (%)
Generalized 89 (25)
Abdomen 79 (22)
Lower extremity 75 (21)
Chest 53 (15)
Upper extremity 27 (8)
Back 25 (7)
Other 12 (3)
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meaningful reduction in pain scores did not vary with the type 
(p=0.391) and duration of pain (p=0.224) or race (p=0.268).
Regarding the frequency of a meaningful reduction in 
opioid intake, in 52% of ketamine infusions there were 20% 
or greater reductions in opioid intake. The frequency of 
infusions associated with ≥20% reduction in opioid intake 
varied according to duration of ketamine infusion (p=0.030), 
with longer durations infusions being more likely to result 
in a meaningful reduction in opioid intake (data not shown). 
Conversely, the frequency of a meaningful reduction in opioid 
intake did not vary with the clinical diagnosis, type of pain, 
duration of pain, location of pain, age, sex, or race.
Discussion
In this cohort study involving a large number of children, 
adolescents, and young adults, we examined the effects of 
subanesthetic ketamine infusions on pain intensity and opioid 
intake. We found that continuous subanesthetic ketamine 
infusions administered to children, adolescents, and young 
adults with inadequate pain control in a regular inpatient 
care unit setting were safe and not associated with significant 
psychotropic effects or hemodynamic side effects that war-
ranted treatment. We do acknowledge that increases in blood 
pressure could occur during administration of ketamine; 
however, we recorded only instances where changes in blood 
pressure warranted treatment with vasoactive drugs. Further, 
while there were no records of hallucinations, it is possible 
that the presence of hallucinations in young children could 
have manifested as dysphoria and those were not recorded. 
Nevertheless, ketamine was associated with significant 
decreases both in pain scores and opioid intake and these 
effects varied according to clinical diagnosis, infusion dura-
tion, and pain location.
The greatest reductions in pain scores were observed in 
patients with cancer pain and patients with inflammatory 
processes including pancreatitis and Crohn’s disease, whereas 
patients with functional gastrointestinal disorder, diabetes 
mellitus, neurofibromatosis 1, and postural orthostatic 
Figure 2 Differential effect of ketamine on pain scores and opioid intake.
Notes: The box plots show median and 25th and 75th percentiles, and the whiskers 10th and 90th percentiles. (A) Box plots of the changes in pain scores from baseline to 
the day after ketamine discontinuation according to primary clinical diagnosis. Ketamine infusions yielded greater reductions in pain scores in patients with cancer-associated 
pain and patients with IFD (including pancreatitis and Crohn’s disease) and the lowest in patients with FGID and other (cystic fibrosis, diabetes mellitus, neurofibromatosis 1, 
and postural orthostatic tachycardia syndrome), overall difference, p=0.011. (B) Effect of ketamine infusions on pain scores also varied according to the duration of ketamine 
infusion as longer ketamine infusions yielded greater reductions in pain scores (p=0.004). (C) The ketamine effect on opioid intake also varied according to clinical diagnosis 
(p=0.030) as greater reductions in opioid intake were observed in patients with cancer pain and patients with sickle cell disease, whereas lesser reductions were observed 
in patients with accidental trauma and postoperative pain due to surgical trauma (p=0.030). (D) Similar to the observation for pain scores, longer ketamine infusions yielded 
greater reductions in oral morphine-equivalent intake (p=0.022).
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Ketamine for pain management
tachycardia syndrome had less reduction in pain scores. We 
also found that ketamine infusions in patients with cancer 
pain, inflammatory diseases, and postoperative pain were 
associated with a greater (over 75% of infusions) frequency 
of meaningful reduction in pain scores (here defined as a 
≥20% reduction). Therefore, this study is informative in 
that its findings can be used to help design much-needed 
randomized trials to evaluate the effect of ketamine in the 
treatment of pain in children, adolescents, and young adults 
with poorly controlled pain.
Over the past few years, the use of ketamine for the 
treatment of cancer pain has been the focus of significant 
debate.15,24,25 The discussion ensued after publication of a 
randomized placebo-controlled clinical trial enrolling 185 
adult participants with cancer pain, who received ketamine 
or placebo delivered subcutaneously.26 That trial showed 
that ketamine, administered over 5 days in a dose-escalating 
regimen, had no clinical benefit compared to placebo and 
was associated with increased adverse events.26 How-
ever, researchers argue that the trial used a subcutaneous 
regimen not commonly utilized, the ketamine doses were 
escalated rapidly, and the study population was very het-
erogeneous, all of which are potential limitations of that 
trial.25 Therefore, researchers argue that those issues should 
tailor the interpretation of the findings26 and those negative 
results should not discard the potential role of ketamine 
in patients with cancer pain.25 After publication of those 
negative results, a survey of clinicians demonstrated that 
the practice of using ketamine was continued by 30% of 
the respondents24 and the use of ketamine to treat cancer 
pain and other types of pain by many specialists has con-
tinued.19,24 On balance, one must recognize that the existing 
data on the use of ketamine in children with cancer pain 
are very limited, most reports consist of small case series, 
and randomized clinical trials of ketamine to treat cancer 
pain in children are lacking. Nevertheless, we have sided 
with those who argue that, while clinical trials are needed, 
the practice of using ketamine in children with cancer 
pain might be one to be adopted when other options are 
unavailable.
Figure 3 Proportion of ketamine infusions associated with a clinically meaningful reduction in pain scores.
Notes: The stacked bars show the proportion of infusions associated with meaningful (≥20% reduction, white bars) and nonmeaningful reductions (<20% reduction, dotted 
bars). We defined a clinically meaningful reduction as a ≥20% reduction in pain scores from baseline to the day after ketamine discontinuation. The proportion of infusions 
that yielded a meaningful reduction varied according to clinical diagnosis (A, overall effect, p=0.003), pain location (B, p=0.012), age (C, p=0.039), and duration of infusion 
(D, p=0.017).
Abbreviations: CA, cancer; IFD, inflammatory disease; SCD, sickle cell disease; POP, postoperative pain; AT, accidental trauma; OT, other; FGID, functional gastrointestinal 
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Concerning acute postoperative pain, we found in the 
present study that the opioid-sparing effect of ketamine was 
minimal. This finding is consistent with our results from a 
previous randomized placebo-controlled trial, where ket-
amine administered in the intraoperative and postoperative 
periods did not yield an opioid-sparing effect in adolescents 
with scoliosis undergoing spinal fusion.11 Interestingly, a 
more recent trial and a new meta-analysis12 also showed lack 
of beneficial effect of ketamine in postoperative pain.27 It is 
important to note that one limitation of the most recent study 
in adolescents undergoing spinal fusion27 as well as ours11 is 
that neither study examined the effect of ketamine on chronic 
postsurgery pain. Nevertheless, our findings from the present 
study are discrepant to those showing that low-dose ketamine 
infusion during the perioperative period yields opioid-sparing 
effects in adults undergoing major surgeries.28 While we 
acknowledge that, in adults, there are data to support the use 
of ketamine in the perioperative period, in our institution, we 
no longer routinely use ketamine to treat postoperative pain 
in our pediatric patients.
One must acknowledge the limitations of this study, 
which call for caution in interpreting its results. First, we 
report on the use of ketamine in a heterogeneous population 
of children, adolescents, and young adults and lack a con-
trol group. Further, while there was consistency regarding 
the ketamine administration regimen and indications for its 
use, timing of administration, and titration of opioids and 
ketamine doses were left to the discretion of the pain medi-
cine attending. Additionally, for the purpose of this study, 
we regarded ketamine infusions administered to the same 
patients as independent infusions and we did not account 
for the potential confounding effect of repeated measures by 
repeatedly administering ketamine to some patients.
Conclusion
In conclusion, despite its limitations, this study suggests 
that in an inpatient setting, the treatment of pain in children, 
adolescents, and young adults with subanesthetic doses of 
ketamine is feasible and safe in regular patient care units. 
The study is also informative in that it suggests that ket-
amine might have a differential beneficial effect in patients 
with certain pain syndromes. Additionally, this study raises 
a number of hypotheses to be tested in future clinical trials 
to more definitively determine which patients would benefit 
from this therapeutic modality. Finally, our findings can be 
used to determine sample and effect sizes for future random-
ized trials to evaluate the role of ketamine for the treatment 
of pain in children, adolescents, and young adults.
Acknowledgments
The authors are grateful to the nursing staff from the 
Children’s National Health System for their excellent care 
of our patients and their families and to members of the 
Department of Anesthesia, and Pain Medicine, Critical 
Care, Acute Care, Pharmacy, the Department of Profes-
sional Practice and Nursing Research, the Department of 
Nursing Staff Development for the development of the low 
dose ketamine administration program at the Children’s 
National Health System. This study was funded by a grant 
(RAC 3000193) from the Sheik Zayed Institute for Pediatric 
Surgical Innovation. 
Disclosure
This article was prepared while Zenaide MN Quezado, MD 
was employed at the Children’s National Health System. The 
opinions expressed in this article are the author’s own and do 
not reflect the view of the National Institutes of Health, the 
Department of Health and Human Services, or the United 
States government. The authors report no other conflicts of 
interest in this work.
References
 1. Corssen G, Miyasaka M, Domino EF. Changing concepts in pain control 
during surgery: dissociative anesthesia with CI-581. A progress report. 
Anesth Analg. 1968;47(6):746–759.
 2. Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anaesthetics, 
ketamine and phencyclidine, selectively reduce excitation of central 
mammalian neurones by N-methyl-aspartate. Br J Pharmacol. 1983; 
79(2):565–575.
 3. Mellon RD, Simone AF, Rappaport BA. Use of anesthetic agents in 
neonates and young children. Anesth Analg. 2007;104(3):509–520.
 4. Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on 
trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar 
depression. Arch Gen Psychiatry. 2010;67(8):793–802.
 5. Finkel JC, Pestieau SR, Quezado ZM. Ketamine as an adjuvant for treat-
ment of cancer pain in children and adolescents. J Pain. 2007;8(6):515–521.
 6. Sheehy KA, Muller EA, Lippold C, Nouraie M, Finkel JC, Quezado ZM. 
Subanesthetic ketamine infusions for the treatment of children and adoles-
cents with chronic pain: a longitudinal study. BMC Pediatr. 2015;15(1):198.
 7. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain 
hypersensitivity by central neural plasticity. J Pain. 2009;10(9):895–926.
 8. Trujillo KA. Are NMDA receptors involved in opiate-induced neural 
and behavioral plasticity? A review of preclinical studies. Psychophar-
macology (Berl). 2000;151(2–3):121–141.
 9. Angst MS, Koppert W, Pahl I, Clark DJ, Schmelz M. Short-term infusion 
of the mu-opioid agonist remifentanil in humans causes hyperalgesia 
during withdrawal. Pain. 2003;106(1–2):49–57.
10. Tawfic QA. A review of the use of ketamine in pain management. 
J Opioid Manag. 2013;9(5):379–388.
11. Pestieau SR, Finkel JC, Junqueira MM, et al. Prolonged perioperative 
infusion of low-dose ketamine does not alter opioid use after pediatric 
scoliosis surgery. Paediatr Anaesth. 2014;24(6):582–590.
12. Michelet D, Hilly J, Skhiri A, et al. Opioid-sparing effect of ketamine 
in children: a meta-analysis and trial sequential analysis of published 
studies. Paediatr Drugs. 2016;18(6):421–433.
13. Connolly SB, Prager JP, Harden RN. A systematic review of ketamine 































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Journal of Pain Research 2017:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Journal of Pain Research
Publish your work in this journal
Submit your manuscript here:  https://www.dovepress.com/journal-of-pain-research-journal 
The Journal of Pain Research is an international, peer reviewed, open 
access, online journal that welcomes laboratory and clinical findings 
in the fields of pain research and the prevention and management 
of pain. Original research, reviews, symposium reports, hypoth-
esis formation and commentaries are all considered for publication. 
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. Visit 




Ketamine for pain management
14. Laskowski K, Stirling A, McKay WP, Lim HJ. A systematic review 
of intravenous ketamine for postoperative analgesia. Can J Anaesth. 
2011;58(10):911–923.
15. Bell RF, Eccleston C, Kalso EA. Ketamine as an adjuvant to opioids 
for cancer pain. Cochrane Database Syst Rev. 2012;11:Cd003351.
16. Goebel A, Barker C, Turner-Stokes L, et al. Complex Regional Pain 
Syndrome in Adults: UK Guidelines for Diagnosis, Referral and Man-
agement in Primary and Secondary Care. London: Royal College of 
Physicians; 2012.
17. Perez RS, Zollinger PE, Dijkstra PU, et al. Evidence based guidelines 
for complex regional pain syndrome type 1. BMC Neurol. 2010;10:20.
18. Butler FK, Kotwal RS, Buckenmaier CC 3rd, et al. A triple-option 
analgesia plan for tactical combat casualty care: TCCC guidelines 
change 13-04. J Spec Oper Med. 2014;14(1):13–25.
19. Martinez V, Derivaux B, Beloeil H; Regional Anaesthesia and the Pain 
Committee of the French Society of Anaesthesiology and Intensive 
Care. Ketamine for pain management in France, an observational survey. 
Anaesth Crit Care Pain Med. 2015;34(6):357–361.
20. Lo TC, Yeung ST, Lee S, Skavinski K, Liao S. Reduction of central 
neuropathic pain with ketamine infusion in a patient with Ehlers-Danlos 
syndrome: a case report. J Pain Res. 2016;9:683–687.
21. Carr DB, Goudas LC, Denman WT, et al. Safety and efficacy of intra-
nasal ketamine for the treatment of breakthrough pain in patients with 
chronic pain: a randomized, double-blind, placebo-controlled, crossover 
study. Pain. 2004;108(1–2):17–27.
22.  Mercadante S, Ferrera P, Villari P, Casuccio A, Intravaia G, Mangione S. 
Frequency, indications, outcomes, and predictive factors of opioid 
switching in an acute palliative care unit. J Pain Symptom Manage. 2009; 
37(4):632–641.
23. Hirschfeld G, Wager J, Schmidt P, Zernikow B. Minimally clinically 
significant differences for adolescents with chronic pain-variability of 
ROC-based cut points. J Pain. 2014;15(1):32–39.
24. Hardy JR, Spruyt O, Quinn SJ, Devilee LR, Currow DC. Implement-
ing practice change in chronic cancer pain management: clinician 
response to a phase III study of ketamine. Intern Med J. 2014;44(6): 
586–591.
25.  Bell RF, Jaksch W, Kalso EA. Interpreting the evidence: reply to Spruyt 
et al. J Pain Symptom Manage. 2014;47(4):e2–e4.
26.  Hardy J, Quinn S, Fazekas B, et al. Randomized, double-blind, placebo-
controlled study to assess the efficacy and toxicity of subcutaneous 
ketamine in the management of cancer pain. J Clin Oncol. 2012;30(29): 
3611–3617.
27.  Perello M, Artes D, Pascuets C, Esteban E, Ey AM. Prolonged perio-
perative low-dose ketamine does not improve short and long-term 
outcomes after pediatric idiopathic scoliosis surgery. Spine (Phila Pa 
1976). 2017;42(5):E304–E312.
28.  Guillou N, Tanguy M, Seguin P, Branger B, Campion JP, Malledant Y. 
The effects of small-dose ketamine on morphine consumption in surgi-
































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
